| Name | Title | Contact Details |
|---|
Pionyr Immunotherapeutics discovers and develops first-in-class biologic drugs that fine-tune natural immune responses to increase immune defenses for diseases such as cancer, or to dampen immune responses in autoimmune diseases.
Melinta Therapeutics, Inc. (NASDAQ:MLNT) is the largest pure-play antibiotics company, dedicated to saving lives threatened by the global public health crisis of bacterial infections through the development and commercialization of novel antibiotics that provide new therapeutic solutions. Its four marketed products include Baxdela™ (delafloxacin), Vabomere™ (meropenem and vaborbactam), Orbactiv® (oritavancin), and Minocin® (minocycline) for Injection. It also has an extensive pipeline of preclinical and clinical-stage products representing many important classes of antibiotics, each targeted at a different segment of the anti-infective market. Together, this portfolio provides Melinta with the unique ability to provide providers and patients with a range of solutions that can meet the tremendous need for novel antibiotics treating serious infections.
We are dedicated to developing and commercializing effective and broadly applicable interventions for food allergy. Food allergy is a disease of the immune system that is triggered by an exceptionally broad range of commonly allergenic foods such as cow’s milk, eggs, tree nuts, peanuts, shellfish and even sesame. In a perfect world, the human immune system would adapt to all foods. However, in tens of millions of people, the immune system wrongly recognizes some food proteins as harmful and does not adapt. We envision a world where, with help from oral immunotherapy, the immune system can adapt to nearly all food allergens. And we built our inspiration into our name—Alladapt. Alladapt was co-founded in 2018 in Palo Alto, California, by allergist and protein biochemist Kari Nadeau, MD, PhD, and biotechnology entrepreneur, Ashley Dombkowski, PhD. Academic clinical research conducted by Dr. Nadeau has demonstrated that a food allergic immune system in an individual person can be receptive to remodeling by gradually increasing exposure, under tightly controlled clinical supervision, to the proteins that activate the inappropriate cascade of reactions. This work, combined with research illuminating disease mechanisms and pathways, led the founders to envision a biopharmaceutical intervention capable of addressing food allergy provoked by a wide-ranging set of antigens. Food allergy is a serious disease, with potentially life-threatening consequences. The disease has grown dramatically in recent years and now affects more than 6 million children¹ and 26 million adults² in the United States alone. Importantly, about half of people with food allergy are reactive to multiple foods, which further increases the risk of anaphylaxis due to accidental ingestion. The chronic, unpredictable components of this disease can elevate anxiety in patients and their families, and place extreme limitations on their lives. It is our goal to help patients experience more of life’s magical moments with less fear and greater confidence.
Glympse Bio is developing a powerful new paradigm in diagnostics to enable noninvasive and predictive monitoring of multiple human diseases.
DFM is a Morristown, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.